U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07730190) titled 'A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors' on July 22.
Brief Summary: TQB6426 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Preclinical studies have demonstrated its potent anti-tumor activity coupled with a favorable therapeutic safety window, which provides sufficient pharmacological and toxicological evidence to support the initiation of human clinical trials.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Malignancies
Intervention:
DRUG: TQB6426 for Injection
TQB64...